Therapeutic Results of Two Regimens for Childhood Acute Myelogenous Leukemia.
- Author:
Hyun Ju PARK
1
;
Won Sang YOON
;
Chan Jong KIM
;
Hyun Ah OH
;
Hoon KOOK
;
Tai Ju HWANG
Author Information
1. Department of Pediatrics, Chonnam University Medical School, Kwangju, Korea. hoonkook@chonnam.chonnam.ac.kr
- Publication Type:Original Article
- Keywords:
Acute myelogenous leukemia;
Children;
Remission induction;
Relapse;
Disease-free survival
- MeSH:
Child;
Disease-Free Survival;
Humans;
Jeollanam-do;
Leukemia, Myeloid, Acute*;
Recurrence;
Remission Induction;
Retrospective Studies;
Survival Rate
- From:Korean Journal of Pediatric Hematology-Oncology
1999;6(1):68-77
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The purpose of this study was to compare the therapeutic results between the two groups of children with acute myelogenous leukemia (AML) who were treated either by 3-year Okayama regimen or by 2-year KSBRM regimen. METHODS: The subjects were 38 newly diagnosed AML patients at Chonnam University Hospital from Apr. 1991 to Dec. 1998. Until April, 1994, 10 patients were treated by the Okayama regimen for 3 years while 28 patients received KSBRM regimen for 2 years thereafter. The remission induction rate, relapse rate, and survival rate were compared retrospectively between the two groups. RESULTS: 1) The remission induction rate was 78.9% (30/38): Okayama group, 80.0% (8/10); KSBRM group, 78.6% (22/28). 2) The relapse rate after remission in the Okayama group was 37.5% (3/8) while that in the KSBRM group was 27.3% (6/22). 3) Deaths were encountered in 16 patients (42.1%): 60.0% (6/10) of Okayama group vs 35.7% (10/28) of KSBRM group (P=0.27). 4) Kaplan-Meier 3-year disease free survival (DFS) for all of the patients was 45.2%. The 3-year DFS was 40.0% for Okayama group and 48.2% for KSBRM group, respectively. The remission induction rate, relapse rate and DFS rate were not different between the two groups. CONCLUSION: The current study showed that KSBRM regimen was as equivalent as Okayama regimen for remission induction rate, relapse rate and 3-year Kaplan-Meier DFS despite the advantage of shortening of treatment duration by 1 year.
